DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for myxoid chondrosarcoma — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMyxoid chondrosarcoma maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for myxoid chondrosarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
isocitrate dehydrogenase (NADP(+)) 1 (IDH1) — IDH1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ictdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6BKX · 1.65 Å · ligand ISOCITRIC ACID (ICT). Experimental structure, not a prediction.
What the evidence adds up to
Two case reports from 2014 describe extraskeletal myxoid chondrosarcoma in the buttock and knee, and a separate report describes primary myxoid chondrosarcoma of the breast. The breast case was managed with conservative surgery, and the authors state that the disease is resistant to chemotherapy and radiotherapy. A 2022 case report describes a myxoid chondrosarcoma in the fourth metacarpal of a 53-year-old man. The tumour was treated with wide surgical excision using liquid nitrogen cryotherapy, followed by local radiotherapy at a total dose of 50 Gy and adjuvant chemotherapy. No relapse was observed during a 12-month post-operative follow-up.
The 2022 report notes that the role of chemotherapy and radiotherapy on soft tissue chondrosarcoma is still under study. The 2014 breast report explicitly states the disease is resistant to chemotherapy and radiotherapy. The 2022 case is a single patient with a 12-month follow-up, which is too short to assess long-term recurrence or metastasis risk. The 2014 reports are purely descriptive and offer no treatment outcome data beyond the surgical approach.
No drug is mentioned in any of these abstracts. No systemic therapy is evaluated. The evidence consists entirely of case reports, with no controlled trials, no patient cohorts, and no comparative data. What is missing is any clinical trial testing a specific drug, any prospective study with survival or response rate endpoints, and any systematic investigation of patient stratification by molecular subtype or prior treatment.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Oncology Letters · 2014 · 9 citations · open access
Extraskeletal myxoid chondrosarcoma: A report of two cases
AbstractExtraskeletal myxoid chondrosarcoma (EMC) is a relatively rare but well-defined neoplasm. This report describes two patients, one with EMC of the buttock and one with EMC of the knee. The two cases presented with large lobed masses and long T1 and T2 signaling identified by magnetic resonance imaging (MRI). An enhanced MRI scan demonstrated enhancement of the tumors. The tumors were composed of strands or cords of oval and spindle cells embedded in abundant myxoid stroma. Pathology results confirmed EMC.
Annals of The Royal College of Surgeons of England · 2014 · 5 citations · open access
Primary myxoid chondrosarcoma of the breast
AbstractPrimary breast chondrosarcoma has been rarely reported in the literature. Conservative breast surgery has never been part of the management of previously reported cases. Surgery remains the mainstay management of such a disease as it is resistant to chemotherapy and radiotherapy. In this report, we present a case of rare primary myxoid chondrosarcoma of the breast that was managed successfully with a conservative approach.
International Journal of Health Sciences · 2022 · 0 citations · open access
A rare case study of myxoid chondrosarcoma in 4th metacarpal hand
AbstractBackground: myxoid chondrosarcoma (MC) is a rare soft tissue tumor that typically affects the lower limbs of men between the ages of 50 and 60. EMC of the Metacarpals is rare of rarest with a high risk of local recurrence and distant metastasis. A planned surgical excision in sarcoma referral centers (SRCs) is mandatory to obtain the best outcome. The role of chemotherapy (CHT) and Radiotherapy (RT) on soft tissue chondrosarcoma is still under study. Case presentation: A 53-year-old male patient presented to our hospital with a history of swelling in the left hand for 6 months. Radiological and histological study reveals diagnosis of extra skeletal chondrosarcoma. Wide surgical excision was done using cryotherapy in form of liquid nitrogen. Biopsy was taken from the site and sent to immunohistochemistry which proved the diagnosis. A Kirschner wire embedded with polymethylmethacrylate cement was placed in defect site and checked for movements. imaging exams did not reveal distant metastasis or residual disease. Local radiotherapy was administered with a total dose of 50 Gy and adjuvant chemotherapy was given. No relapse occurred in a 12-months post-operative follow up. Conclusions: The case here described suggests the importance of patient’s management in SRCs.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
